Dr. Davis has a 35+ year career in the discovery and development of novel therapeutics at major pharmaceutical and biotechnology companies, including the last 20 years at Johnson & Johnson. Hugh is an expert in the early development of innovative biologics, from asset discovery and characterization through IND and BLA regulatory submissions across the world, including the US, China, EU and Japan.

Together with his team, Dr. Davis was instrumental in the development and approval of many biologic therapies at J&J including Remicade®, Stelara®, Simponi®, Sylvant®, Darzalex® and Tremfya®. Hugh was the VP and Head of the Biologics Development Sciences department in Janssen Biotherapeutics (JBIO), leading a group of up to 200+ scientists in the biophysical characterization of discovery assets, translational methods to characterize leads, employ modeling and simulation to determine starting doses for first-in-human trials and develop novel clinical trial designs to achieve early clinical POC assessment of novel therapeutics.

In addition, over the last 5-6 years in JBIO at J&J, Hugh was also the China Biologics Leader.  In this role Hugh worked with the China Innovation group in Shanghai to meet with many CEO and CSOs to identify key assets and discovery platforms to partner or license into J&J.  In this way the CAR-T programs from Legend Biotech were identified and licensed by the Janssen Oncology group.

Following his tenure at J&J, Dr. Davis took the role of Chief Business Officer at Frontage Laboratories, leading the company to a very successful IPO, bringing in over $200 MM USD, on the Hong Kong Exchange (HKSE: 1521) in May of 2019.

Dr. Davis holds a Ph.D. degree in Biochemistry from Villanova University and completed post-Doctoral training at Centocor, Inc. where he patented the characterization of the tumor biomarker for ovarian cancer, CA125.